Study will evaluate ELI-002 7P in combination with chemotherapy and a checkpoint inhibitor (“CPI”) in the neoadjuvant ...

Oncolytics Biotech® Inc. (Nasdaq: ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing ...

New research from Indiana University School of Medicine scientists has revealed that a well-known cancer-fighting gene also ...

Discover Immuneering’s latest breakthrough: atebimetinib delivers unprecedented survival rates in first-line pancreatic cancer.

Study will evaluate ELI-002 7P in combination with chemotherapy and a checkpoint inhibitor (“CPI”) in the neoadjuvant settingTrial is anticipated ...

What's new in proton therapy? Read the latest news and views from Fred Hutch's proton therapy facility’s patients and ...

Immuneering Corporation - Special CallCompany ParticipantsBenjamin Zeskind - Co-Founder, President, CEO & DirectorConference Call ...

She has helped robots learn to get around indoors and pick up balls from the ground. And she has developed computer programs ...

Onconic Therapeutics announced on September 29 that it has received approval from the Ministry of Food and Drug Safety for a Phase 2 clinical trial ...

Cancer cells are pretty bold and clever—they hijack cellular survival and healing processes in order to fuel their growth, ...

A JAMA study finds cancer diagnoses in Americans under 50 have doubled since 1992, but deaths remain flat—raising concern about overdiagnosis.

Oncolytics Biotech announced an update on its proposed registration-directed clinical trial for first-line pancreatic cancer treatment, featuring a three-arm design to evaluate the efficacy of ...